Breaking the barriers in cancer care: The next generation of herpes simplex virus-based oncolytic immunotherapies for cancer treatment

Since the US Food and Drug Administration first approved talimogene laherparepvec for the treatment of melanoma in 2015, the field of oncolytic immunotherapy (OI) has rapidly evolved. There are numerous ongoing clinical studies assessing the clinical activity of OIs across a wide range of tumor type...

Descripción completa

Detalles Bibliográficos
Autores principales: Khushalani, Nikhil I., Harrington, Kevin J., Melcher, Alan, Bommareddy, Praveen K., Zamarin, Dmitriy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10570124/
https://www.ncbi.nlm.nih.gov/pubmed/37841530
http://dx.doi.org/10.1016/j.omto.2023.100729

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10570124/
https://www.ncbi.nlm.nih.gov/pubmed/37841530
http://dx.doi.org/10.1016/j.omto.2023.100729

Ejemplares similares